Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States

BACKGROUND: The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by the US Food and Drug Administration, has demonstrated clinically relevant weigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Nina, Wang, Jessie, Burudpakdee, Chakkarin, Song, Yan, Ramasamy, Abhilasha, Xie, Yanwen, Sun, Rochelle, Kumar, Neela, Wu, Eric Q, Sullivan, Sean D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372962/
https://www.ncbi.nlm.nih.gov/pubmed/35737858
http://dx.doi.org/10.18553/jmcp.2022.28.7.740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372962/
https://www.ncbi.nlm.nih.gov/pubmed/35737858
http://dx.doi.org/10.18553/jmcp.2022.28.7.740

Ejemplares similares